KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

Maurizio Martini, Alessandra Cassano, Luigi Maria Larocca, Michele Basso, Antonia Strippoli, Armando Orlandi, Maria Alessandra Calegari, Giovanni Schinzari, Mariantonietta Di Salvatore, Tonia Cenci, Carlo Antonio Barone

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

26 Citazioni (Scopus)

Fingerprint Entra nei temi di ricerca di 'KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients'. Insieme formano una fingerprint unica.

Medicine & Life Sciences